MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,166K
Free Cash flow
-$15,488K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the issuance of co...
Proceeds from maturities of mark...
Collaboration revenue from a rel...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Deferred revenue from a related ...
General and administrative
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue from a related party
13,374
8,213
42,469
29,834
Total research and development
14,917
14,900
17,250
47,563
General and administrative
4,801
4,683
5,420
14,188
Interest and other income, net
2,487
2,291
2,291
3,705
Income tax expense
-
-
0
0
Net loss
-3,857
-9,079
22,090
-9,196
Depreciation and amortization
20
26
32
32
Stock-based compensation
2,416
1,116
1,461
1,670
Net accretion of investments in marketable debt securities
768
789
828
631
Non-cash rent expense
203
204
204
209
Realized gain on investments in marketable debt securities
-
-
3
-
Accounts receivable from collaboration with a related party
371
-523
62
912
Prepaid expenses and other current assets
1,234
92
2,126
856
Accounts payable
-70
-42
-512
940
Accrued research and development expenses
469
-849
-671
1,367
Other accrued expenses
678
-5,085
2,021
2,321
Deferred revenue from a related party
-12,772
-7,828
-7,174
-9,877
Operating lease liabilities
-202
-202
-195
-200
Net cash used in operating activities
-15,488
-22,097
14,237
-15,133
Proceeds from maturities of marketable securities
53,755
57,600
32,800
22,700
Purchases of marketable securities
145,836
62,963
11,553
180,929
Purchases of property and equipment
0
19
24
42
Net cash (used in) provided by investing activities
-92,081
-5,382
21,223
-158,271
Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs
-
-
0
123,600
Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs
-
-
0
42,785
Proceeds from the exercise of warrants
-
-
0
5,510
Proceeds from the issuance of common stock and pre-funded warrants in an underwritten offering, net of issuance costs (12,500 from a related party)
108,080
-
-
-
Proceeds from the issuance of common stock under atm equity offering program, net of issuance costs
0
0
0
0
Proceeds from the issuance of common stock under espp
425
-
368
0
Proceeds from the exercise of stock options
230
149
88
37
Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs
-
-
-
0
Proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs
-
-
0
-
Net cash provided by financing activities
108,735
149
456
171,932
Net decrease in cash and cash equivalents
1,166
-27,330
35,916
-1,472
Cash and cash equivalents at the beginning of the period
31,120
58,450
22,534
38,344
Cash and cash equivalents at the end of the period
32,286
31,120
58,450
22,534
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of common stock...
$108,080K
Proceeds from the
issuance of common stock...
$425K
(19.05%↑ Y/Y)
Proceeds from the
exercise of stock options
$230K
Net cash provided by
financing activities
$108,735K
(4671.17%↑ Y/Y)
Net decrease in cash
and cash...
$1,166K
(108.13%↑ Y/Y)
Canceled cashflow
$107,569K
Proceeds from maturities
of marketable...
$53,755K
(-11.78%↓ Y/Y)
Stock-based compensation
$2,416K
(56.27%↑ Y/Y)
Other accrued
expenses
$678K
(119.62%↑ Y/Y)
Accrued research and
development expenses
$469K
(180.58%↑ Y/Y)
Non-cash rent expense
$203K
(-53.65%↓ Y/Y)
Depreciation and
amortization
$20K
(-69.23%↓ Y/Y)
Net cash (used in)
provided by investing...
-$92,081K
(-490.50%↓ Y/Y)
Net cash used in
operating activities
-$15,488K
(61.47%↑ Y/Y)
Canceled cashflow
$53,755K
Canceled cashflow
$3,786K
Collaboration revenue from a
related party
$13,374K
Interest and other
income, net
$2,487K
Purchases of marketable
securities
$145,836K
(290.44%↑ Y/Y)
Deferred revenue from a
related party
-$12,772K
(32.94%↑ Y/Y)
Net loss
-$3,857K
(79.72%↑ Y/Y)
Canceled cashflow
$15,861K
Prepaid expenses and
other current assets
$1,234K
(231.70%↑ Y/Y)
Net accretion of
investments in marketable...
$768K
(-13.42%↓ Y/Y)
Accounts receivable from
collaboration with a related...
$371K
Operating lease
liabilities
-$202K
(43.26%↑ Y/Y)
Accounts payable
-$70K
(-144.30%↓ Y/Y)
Total research and
development
$14,917K
General and
administrative
$4,801K
Buy us a coffee
ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC. (ASMB)